A Clinical Trial to Evaluate the Safety and Efficacy of ZYH7 Compared to Fenofibrate in Patients With Dyslipidemia
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
ZYH7, a novel peroxisome proliferator-activated receptor (PPAR) alpha agonist, is expected to
decrease triglyceride level and also correct dyslipidemia.